Latest filings (excl ownership)
10-K/A
2023 FY
Annual report (amended)
26 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Apr 24
10-K
2023 FY
Annual report
25 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
17 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Termination of a Material Definitive Agreement
7 Jul 23
8-K
Other Events
28 Jun 23
8-K
Departure of Directors or Certain Officers
23 Jun 23
8-K
Amendments to Articles of Incorporation or Bylaws
9 Jun 23
8-K
Departure of Directors or Certain Officers
30 May 23
8-K
Entry into a Material Definitive Agreement
18 May 23
DEFA14A
Additional proxy soliciting materials
11 May 23
8-K
Changes in Registrant's Certifying Accountant
11 May 23
10-Q
2023 Q1
Quarterly report
10 May 23
8-K
Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
10 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
8-K
Finch Therapeutics Announces Executive Leadership Transitions
25 Apr 23
8-K
Entry into a Material Definitive Agreement
18 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
S-8
Registration of securities for employees
23 Mar 23
10-K
2022 FY
Annual report
23 Mar 23
8-K
Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
23 Mar 23
8-K
Termination of a Material Definitive Agreement
26 Jan 23
8-K
Cost Associated with Exit or Disposal Activities
24 Jan 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Jan 23
8-K
Departure of Directors or Certain Officers
12 Dec 22
8-K
Regulation FD Disclosure
14 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results
10 Nov 22
8-K
Finch Therapeutics Provides Business Update
1 Sep 22
8-K
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
25 Aug 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
8-K
Finch Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results
11 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 22
EFFECT
Notice of effectiveness
3 Jun 22
Latest ownership filings
4
JEFFERY A SMISEK
29 Mar 24
144
Notice of proposed sale of securities
28 Mar 24
SC 13G
Ugwumba Chidozie
13 Dec 23
4
JEFFERY A SMISEK
27 Nov 23
144
Notice of proposed sale of securities
22 Nov 23
4/A
Matthew P. Blischak
23 Jun 23
4
Matthew P. Blischak
9 Jun 23
4
Christian H. Lange
9 Jun 23
4
JEFFERY A SMISEK
9 Jun 23
4
Nicholas Haft
9 Jun 23
4
DOMENIC J FERRANTE
9 Jun 23
4
Susan E Graf
9 Jun 23
4
Chris Shumway
9 Jun 23
3
Matthew P. Blischak
16 May 23
3
LANCE E THIBAULT
16 May 23
4
Marc Blaustein
23 Feb 23
4
Marc Blaustein
25 Oct 22
4
Joseph Vittiglio
25 Oct 22
4
Chris Shumway
15 Jun 22
4
Christian H. Lange
15 Jun 22
4
Marc Blaustein
15 Jun 22
4
Samuel A Hamood
15 Jun 22
4
Joseph Vittiglio
15 Jun 22
4
DOMENIC J FERRANTE
15 Jun 22
4
Susan E Graf
15 Jun 22
4
Joanne L. Viney
15 Jun 22
4
JEFFERY A SMISEK
15 Jun 22
4
Nicholas Haft
15 Jun 22
4
Marc Blaustein
28 Feb 22
4
GREGORY D PERRY
28 Feb 22
4
Joseph Vittiglio
28 Feb 22
SC 13G
Walton Thomas Layton
14 Feb 22
SC 13G
Ugwumba Chidozie
14 Feb 22
4
Nicholas Haft
22 Dec 21
4
Joseph Vittiglio
21 Dec 21
4
Samuel A Hamood
5 Oct 21
3
Samuel A Hamood
5 Oct 21
4
Marc Blaustein
10 Sep 21
3
Marc Blaustein
10 Sep 21
4
Joanne L. Viney
14 May 21